All News

Caris Life Sciences (Irving, TX) has announced the launch of its urologic pathology practice, available through its subsidiary Caris Diagnostics.

Blue Shield of California now covers the Renessa System (Novasys Medical, Inc., Newark, CA) treatment for non-pregnant women diagnosed with moderate to severe stress urinary incontinence who are unable or unwilling to undergo surgery.

Cancer often leads to significant and long-term disruption in sexual function and intimacy, regardless of the type of cancer or how far along the patient is in the treatment plan, say researchers from Duke Clinical Research Institute, Durham, NC.

Men with prostate cancer are at increased risk of thromboembolism, particularly those receiving hormone therapy, according to a recent study.

The American Board of Medical Specialties, which oversees the certification of physician specialists in the United States, has appointed Gerald H. Jordan, MD, to its board.

Hannelore Heemers, PhD, has been appointed assistant professor in the department of urology and member of the genitourinary program at Roswell Park Cancer Institute in Buffalo, NY.

Beaumont Hospitals, Royal Oak, MI, has opened a new Women's Urology Center that the hospital says is the first center in the Midwest dedicated and designed exclusively for women's urological care and sexual health.

Infertile men are at nearly three times greater risk for developing clinically significant prostate cancer than the average man, according to recently published research.

Although the mandatory compliance date for implementation is October 1, 2013, you'll need to accomplish much between now and then to make documentation and diagnosis reporting as seamless as possible.

A form of testosterone replacement therapy that uses implantable testosterone pellets (Testopel) is a viable alternative to existing treatments for hypogonadism, with a number of practical advantages for patients.

The addition of a short course of hormone therapy to radiation improves outcomes for patients with intermediate-risk, early-stage prostate cancer.

Finding a solution would seem to be a core issue for those interested in reforming a health care system in which Medicare is such a core component.

However you decide to market and promote your practice, you will want to measure the impact and results of your efforts.

New urology products and services on the horizon.

Newly available urology products and services.

Use of nutritional supplements providing vitamins and higher doses of antioxidants does not appear to interfere with the efficacy of radiation therapy for prostate cancer.

Stereotactic body radiotherapy (SBRT) for prostate cancer appears to have the same impact on sexual function as other forms of radiotherapy.

Urologists share the software and technology they would most recommend to colleagues.

AUA has formed a task force to create a pool of qualified surgeons who will teach and perform male circumcision to help prevent the spread of HIV infection in sub-Saharan Africa.

The oral angiogenesis inhibitor pazopanib (Votrient) more than doubled progression-free survival versus placebo in a randomized, phase III trial of patients with advanced renal cell carcinoma.

The study adds to a growing body of literature now suggesting that ADT in combination with EBRT is not indicated for the low-risk patient.

Low-income prostate cancer patients are far more likely to undergo surgery for their disease if they are treated in a county hospital versus a private provider.

Medical practices around the country face continued challenges with managing a diverse work force that spans three generations.

Often neglected in the life insurance strategy is the estate tax consequence associated with the ownership and ultimate payout of the insurance policy's death benefit.

In children who show signs of readiness, toilet training is best initiated between the ages of 27 and 32 months.

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes phase II, III, and IV erectile dysfunction trials that are currently recruiting participants. This list is current as of March 17, 2010.

Recently published data analyses provide further evidence in support of assessing sexual health as a simple, low-cost strategy to augment traditional screening for cardiovascular disease (CVD) risk in men.